This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Olak, J. Articles by Ng, A. Search for Related Content PubMed PubMed Citation Articles by Olak, J. Articles by Ng, A.

Diagnosis and Treatment of Early-Stage Non-Small Cell Lung Cancer

The University of Chicago, Department of Surgery, Section of Thoracic Surgery, Chicago, Illinois, USA

Correspondence: Jemi Olak, M.D., Department of Surgery, The University of Chicago, 5841 S. Maryland Avenue, MC 5035, Chicago, IL 60637, USA. Telephone: 312-702-2644; Fax: 312-702-2642; e-mail: jolak{at}surgery.bsd.uchicago.edu

Current recommendations for the diagnostic work-up and treatment of early-stage non-small cell lung cancer are presented, and the rationale behind these recommendations is reviewed. Early-stage disease is found in approximately 30% of patients at initial presentation. Surgeons continue to be uncertain with regard to how extensively they should look for metastatic disease, especially in asymptomatic patients with newly diagnosed lung cancer. While it is generally agreed that surgery is an important component of treatment for stage I and II non-small cell lung cancer, the role of adjuvant therapies in early-stage disease merits further study. Stage IIIa lung cancer is evolving as a disease for which multimodality therapy is likely to play a role, but the timing and sequence of treatment is an area of intense investigation. The recommendations made in this article are based upon the results of randomized clinical trials whenever possible.

Key Words. Non-small cell lung cancer • Diagnosis • Treatment